Skip to main content

Table 1 Clinical characteristics at baseline visit by number of previous bDMARDs

From: Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

  Total Bionaïve 1 previous bDMARD ≥ 2 previous bDMARDs
Number of patients (%) 2716 453 (16.7) 741 (27.3) 1522 (56)
Female sex (%) 2176 (80.1) 325 (71.7) 599 (80.8) 1252 (82.3)
Age at treatment start (years); mean (SD) 59.3 (13.3) 61.7 (14.0) 60.7 (12.9) 57.8 (13.0)
Duration of RA at treatment start (years); mean (SD) 14.2 (11.4) 9.5 (11.1) 14.4 (11.8) 15.5 (10.8)
Intravenous treatment 1365 (50.3%) 194 (42.8%) 381 (51.8%) 790 (52.1%)
Subcutaneous treatment 1338 (49.3%) 257 (57.0%) 355 (48.2%) 726 (47.9%)
ESR (mm 1st h); median (IQR) 23 (11–42) 23 (12–42) 23.5 (12–40.25) 22 (10–41)
CRP (mg/l); median (IQR) 9 (3.5–23) 11 (5–24) 8 (3.48–23) 8 (3–22)
DAS28; mean (SD) 4.98 (1.29) 5.01 (1.23) 4.93 (1.28) 4.99 (1.31)
DAS28-CRP; mean (SD) 4.66 (1.13) 4.64 (1.14) 4.57 (1.13) 4.70 (1.13)
VAS pain (0–100); mean (SD) 60 (23) 58 (24) 59 (23) 62 (22)
VAS global (0–100); mean (SD) 60 (22) 56 (23) 60 (23) 62 (22)
Swollen joint count (0–28); median (IQR) 5 (2–9) 6 (3–10) 5 (2–8) 5 (2–9)
Tender joint count (0–28); median (IQR) 6 (3–10) 6 (2–11) 6 (3–10) 6 (3–11)
HAQ-DI (0–3); mean (SD) 1.32 (0.63) 1.16 (0.63) 1.30 (0.65) 1.37 (0.62)
Physicians global (0–4); median (IQR) 2 (2–3) 2 (2–3) 2 (2–3) 2 (2–3)
Current methotrexate 1288 (57%) 196 (55%) 373 (61%) 719 (55%)
Current glucocorticoids 1316 (49%) 176 (39%) 345 (47%) 795 (52%)
Glucocorticoids dose in mg, prednisolone equivalent; mean (SD) 7.5 (4.2) 7.6 (3.9) 6.9 (4.0) 7.8 (4.3)
Current csDMARD 1489 (55%) 237 (52%) 425 (57%) 827 (54%)
  1. Missing data: Duration of RA at treatment start (years), 17; intravenous/subcutaneous treatment, 13; ESR, 714; CRP, 580; DAS 28, 921; CRP, 811; VAS pain, 748; VAS global, 711; swollen joint count, 624; tender joint count, 625; HAQ-DI, 825; physician global, 711; current methotrexate, 439